Duloxetine Capsule, Delayed Release
Product Images NDC 70518-1765

15 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-1765). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 01)

Structure (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 01)
Chemical structure diagram of duloxetine hydrochloride, showing its molecular framework including a naphthalene moiety, a thiophene ring, and an amine group associated with hydrochloride (HCl).*
FDA Label Image

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 02)

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 02)
A Kaplan-Meier estimator method graph showing the proportion of patients with relapse over time from randomization to relapse in days. The plot compares two treatments: Duloxetine and Placebo, with the Duloxetine curve lower than Placebo, indicating fewer relapses over approximately 200 days.*
FDA Label Image

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 03)

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 03)
A Kaplan-Meier estimator graph showing the proportion of patients with relapse over time in days from randomization for Duloxetine and placebo treatments. The graph plots relapse proportion on the vertical axis against time in days on the horizontal axis, comparing Duloxetine (solid line) and placebo (dashed line).*
FDA Label Image

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 04)

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 04)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine doses (60 mg BID, 60 mg QD, 20 mg QD) and placebo. The graph compares the effectiveness of different Duloxetine dosages to placebo across a range of pain improvement percentages.*
FDA Label Image

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 05)

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 05)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline in a study comparing Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo treatments. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved. The graph includes data points for each group and a legend identifying the three treatment groups.*
FDA Label Image

Fig 5 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 06)

Fig 5 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 06)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The graph shows higher patient improvement percentages with Duloxetine treatments compared to placebo across pain improvement levels.*
FDA Label Image

Fig 6 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 07)

Fig 6 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 07)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 60 mg once daily (alternative notation), and placebo. The y-axis represents the percentage of patients improved, and the x-axis shows percent improvement in pain from baseline, ranging from greater than 0 to 100.*
FDA Label Image

Fig 7 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 08)

Fig 7 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 08)
A line graph showing the percentage of pediatric patients aged 13 to 17 with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12 in Study FM-4. The x-axis represents percent improvement in pain from baseline, ranging from >0 to 100%, and the y-axis shows the percentage of patients improved, from 0 to 100%. Two lines compare Duloxetine 60 mg once daily and placebo, with Duloxetine consistently showing higher percentages of patient improvement across pain relief levels.*
FDA Label Image

Figure 8 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 09)

Figure 8 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 09)
A line chart comparing the percentage of patients improved in pain from baseline, shown as percent improvement in pain (x-axis) versus percentage of patients improved (y-axis). It compares placebo and Duloxetine 60/120 mg once daily groups, with Duloxetine consistently showing higher improvement percentages across the range.*
FDA Label Image

Figure 9 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 10)

Figure 9 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 10)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo groups. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved. Two lines with markers represent each group, with Duloxetine showing higher patient improvement across most levels of pain improvement.*
FDA Label Image

Figure 10 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 11)

Figure 10 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 11)
A line graph comparing percentage of patients improved in pain from baseline between placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF), while the y-axis shows the percentage of patients improved. Duloxetine data is marked with diamonds, placebo with crosses, showing trends across different improvement thresholds.*
FDA Label Image

Mm1 (Duloxetine 30mg 70518 1765 00)

Mm1 (Duloxetine 30mg 70518 1765 00)
Duloxetine 30 mg delayed-release capsules label showing 30 capsules per package, with NDC number 70518-1765-00. Label indicates the capsules are blue and white. The labeler is RemedyRepack Inc., based in Indiana, PA. Dosage instructions and storage conditions are noted, along with a QR code for additional information.*
FDA Label Image

Mm2 (Duloxetine 30mg 70518 1765 01)

Mm2 (Duloxetine 30mg 70518 1765 01)
Duloxetine Capsule delayed-release 30 mg label showing quantity of 90 capsules. Label includes NDC number 70518-1765-01, directions to see insert for usual dosage, and storage instructions. The capsules are described as blue and white. The labeler is RemedyRepack Inc., Indiana, PA, with manufacturer Lupin Ltd, Goa, India mentioned.*
FDA Label Image

Mm3 (Duloxetine 30mg 70518 1765 02)

Mm3 (Duloxetine 30mg 70518 1765 02)
Duloxetine 30 mg delayed-release capsules label showing a quantity of 90 capsules. The medication is packaged by RemedyRepack Inc., with NDC 70518-1765-02. Capsule colors are blue and white. The manufacturer is Lupin Ltd., India. Storage instructions include maintaining 20-25°C (68-77°F) with permitted excursions. The label includes a QR code and typical regulatory information.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Label for Duloxetine 30 mg delayed-release capsules, with a quantity of 30 capsules. The label includes Dosage form as capsule and specifies the labeler as RemedyRepack Inc. The label shows NDC 70518-1765-00 and manufacturing information from Lupin Ltd, Goa, India. Directions reference a package insert and storage instructions are listed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.